



Website
www.alkermes.com

Ticker Symbol
(NASDAQ) ALKS

Contacts
Rebecca Peterson
Vice President, Corporate
Communications

Voice: 781-609-6378

Blair Jackson
Vice President, Business
Development

Voice: 781-609-6594

Corporate Headquarters
Alkermes, Inc.
852 Winter Street
Waltham, MA 02451

Voice: 781-609-6000
Fax: 781-890-0524

Alkermes, Inc. is a fully integrated biotechnology company that develops medicines designed to yield better outcomes and improve patients' lives. Our products, which use novel molecules and innovative drug technologies, target widespread diseases including central nervous system (CNS) disorders, addiction and diabetes. We approach the drug development process from a patient-centric perspective, beginning with a thorough understanding of the challenges patients face on a day-to-day basis. Our products are designed with patient needs and behaviors in mind, with the goal of ensuring that patients consistently take their medication for long-term treatment success.

We partner with some of the world's leading pharmaceutical companies to collaboratively manufacture and market the medicines we develop, and also work independently to create our own therapies. We have built a wide range of capabilities, including innovative research programs, clinical development, large-scale manufacturing, and a commercial presence in the marketplace.

Commercial Products

RISPERDAL® CONSTA®
(risperidone) Long-Acting Injection

Product: RISPERDAL CONSTA is a long-acting injectable form of Janssen's schizophrenia drug, RISPERDAL® (risperidone). Developed utilizing Alkermes' proprietary Medisorb® technology, RISPERDAL CONSTA is administered once every two weeks, rather than daily, for the management of schizophrenia and bipolar I disorder.

Status: Johnson & Johnson's subsidiary, Janssen, markets RISPERDAL CONSTA worldwide. It is commercialized in more than 60 countries, including the U.S., the UK, Japan and Germany.

Market Opportunity: Schizophrenia is a brain disorder that affects 1-2% of the world's population. Until now, extended-release injection formulations of antipsychotics have been available only for older, typical treatments.

Additional Developments: In May 2009, the U.S. Food and Drug Administration (FDA) approved RISPERDAL CONSTA for the treatment of bipolar I disorder.

For product information, please visit
www.risperdalconsta.com.

VIVITROL®

(naltrexone for extended-release injectable suspension)

Product: VIVITROL is an injectable formulation of naltrexone, based on Alkermes' unique Medisorb technology. VIVITROL is designed for once-monthly dosing, eliminating the need for patients to make a daily decision about taking their medicine. Alkermes manufactures VIVITROL at its commercial facility in Ohio and markets the product independently in the U.S. with a focused commercial team. In Russia, Janssen-Cilag, an affiliate company of Cilag GmbH International, is responsible for the commercialization of VIVITROL.

Status: VIVITROL is commercially available for the treatment of alcohol dependence in the U.S. and Russia.

Market Opportunity: Approximately 18 million people in the U.S. are dependent on or abuse alcohol and half of these individuals are alcohol dependent. An estimated 2.6 million people seek treatment for alcohol problems each year.

Additional Developments: In April 2010, Alkermes submitted a supplemental New Drug Application (sNDA) for VIVITROL to the FDA for approval as a treatment for opioid dependence.

For product information, please visit www.vivitrol.com.

Management Team

Richard F. Pops

Chairman, President and Chief Executive Officer

Kathryn L. Biberstein

Senior Vice President and General Counsel

Dennis J. Bucceri

Vice President Regulatory Affairs

Madeline D. Coffin

Vice President Human Resources

Elliot W. Ehrich, M.D.

Senior Vice President Research and Development and Chief Medical Officer

James M. Frates

Senior Vice President Chief Financial Officer

Blair C. Jackson

Vice President, Business Development

Stephen King

Vice President Commercial Operations

Michael J. Landine

Senior Vice President Corporate Development

Rebecca J. Peterson

Vice President, Corporate Communications

Gordon G. Pugh

Senior Vice President and Chief Operating Officer



Alkermes, Inc.

852 Winter Street
Waltham, MA 02451
USA

Tel: 781 609-6000

Fax: 781 890-0524

www.alkermes.com

Clinical Development Programs

Preclinical	Phase I	Phase II	Phase III	Regulatory Review	Approved
RISPERDAL® CONSTA® (Schizophrenia and Bipolar I Disorder)					
VIVITROL® (Alcohol Dependence)					
VIVITROL® (Opioid Dependence)					
BYDUREON™ (Type 2 Diabetes)					
ALKS 33 (Addiction)					
ALKS 37 (OIC)					
ALKS 36 (Pain)					
ALKS 6931 (RA)					
ALKS 9070 (Sz)					
ALKS 7921 (Sz)					

Development Candidates

In collaboration with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company, we are developing BYDUREON™ (exenatide for extended-release injectable suspension), an extended-release formulation for the treatment of type 2 diabetes that contains the same active ingredient as BYETTA® (exenatide) injection.

In addition, we are developing ALKS 33 for the treatment of addiction and other CNS disorders, ALKS 37 for the treatment of opioid-induced constipation, ALKS 36 for the treatment of pain and ALKS 9070 and ALKS 7921 for the treatment of schizophrenia. In collaboration with Acceleron Pharma, Inc., we are applying our Medifusion™ technology to develop ALKS 6931 for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases.

Proprietary Technologies

Medisorb® Technology

Alkermes' injectable extended-release drug delivery system, called the Medisorb® technology, is clinically proven and currently manufactured at commercial levels. This technology can play an important role for the treatment of diseases in which the extended-release formulation of a drug may help to improve outcomes.

Medifusion™ Technology

Alkermes' proprietary long-acting Fc fusion technology platform, called the Medifusion technology, is designed to extend the circulating half-life of proteins and peptides in order to create an effective, long-acting injectable medication. Medifusion extends the half-life of proteins and peptides through the combined action of Fc fusion and hyperglycosylation.

LinkeRx™ Technology

The long-acting proprietary LinkeRx technology platform enables the creation of extended-release injectable versions of antipsychotic therapies and may also be useful in other disease areas in which long action may provide therapeutic benefits.

Manufacturing

With its world class commercial manufacturing facility, Alkermes is well-positioned to support the development, launch and commercialization of its product candidates. A 200,000 square foot cGMP manufacturing facility in Wilmington, Ohio, provides commercial scale manufacturing for extended-release products. RISPERDAL CONSTA and VIVITROL are produced at this location.